National Gilles De La Tourette Study Group
- Conditions
- Tourette Syndrome
- Registration Number
- NCT00169351
- Lead Sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Brief Summary
Tourette syndrome is rare. In France, about 3000 patients have a severe form of the disease. The aim of this study is to collect clinical characteristics in 200 patients with Tourette syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Tourette syndrome
Exclusion Criteria
- severe cognitive disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tic severity in NCT00169351 Tourette Syndrome observational study?
How do dopamine receptor antagonists compare to CBIT in managing tics among NCT00169351 participants?
Which neuroimaging biomarkers correlate with treatment response in NCT00169351 Tourette Syndrome cohort?
What adverse events are associated with antipsychotic use in NCT00169351 severe Tourette Syndrome patients?
How does NCT00169351 data inform development of glutamatergic modulators for Tourette Syndrome?
Trial Locations
- Locations (1)
Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE
🇫🇷Paris, France
Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE🇫🇷Paris, FranceAndréas Hartmann, MD, PhDContact33-142161950hartmann@ccr.jussieu.frYves AGID, MD, PhDPrincipal Investigator